AI kidney diagnostics and buybacks are moving stocks

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 June 14, 2024 | [Read Online]( AI kidney diagnostics and buybacks are moving stocks  [MarketMaster’s Chat]( Good day, 360! Here are our top investing ideas today. These setups look primed! Be the best prepared trader on the Street. And check out our insane [ALL-ACCESS sale.]( Ends at MARKET CLOSE! FOCUS LIST🔎 RNLX - Up over 14% in pre after Medicare issues final coverage determination for kidneyintelX.dkd CRDL - Up over 9% in pre after positive Phase 2 data for Recurrent Pericarditis treatment ZKH - Up over 10% in pre after authorizing $50 million ADR buyback Can’t Decide? Get Them All… All our TOP trading services, that is! [Limited Enrollment to ALL-ACCESS]( Ends In JUST: Contact Stephen or Davis to see if you have any credits or to set up a payment plan –1-800-585-4488 / davis@ragingbull.com HOTLIST🔥 RNLX - Up over 14% in pre after Medicare issues final coverage determination for kidneyintelX.dkd Renalytix Plc (RNLX) develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. In the pre-market this morning, the [company announced]( that Medicare issued a final Local Coverage Determination for the company's kidneyintelX.dkd testing. It’s effective for dates of service on or after August 1, 2024 and the established Medicare price for kidneyintelX.dkd is $950 per test. The stock traded up over 14% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $0.5579. Beyond that targets to the upside are $0.60, $0.70, $0.80, $0.90 and $1. Below $0.5579, targets to the downside are $0.52, $0.50, $0.48 and then a gap fill at $0.4688. CRDL - Up over 9% in pre after positive Phase 2 data for Recurrent Pericarditis treatment Cardiol Therapeutics Inc. (CRDL) is a clinical-stage life sciences company that focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. In the pre-market this morning, the [company announced]( positive topline data from its Phase II MAvERIC-Pilot dtudy investigating CardiolRx(TM) for Recurrent Pericarditis. The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period, as well as normalization of inflammation - as measured by C-reactive protein - in 80% of patients with elevated CRP at baseline. 89% of patients have continued into the extension phase of the study. The stock traded up over 9% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $2.58. Beyond that, $2.70, $2.80, $3 and $3.12 come into play. Below $2.58, targets to the downside are $2.48, $2.40 and then a gap fill at $2.36. Want to Baby Step Into Our Services? [Bullseye Trades is THE place to start…]( When’s the last time you had a FANTASTIC MONDAY?!? [$100 Off When You Join TODAY!]( Jeff’s Next Pick Drops Monday ZKH - Up over 10% in pre after authorizing $50 million ADR buyback ZKH Group Limited (ZKH) is a leading maintenance, repair and operations procurement service platform in China. In the after-hours yesterday, the [company announced]( that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$50 million of its American Depositary Shares over the next 12 months, ending on June 13, 2025. The Company expects to fund the repurchases out of its existing cash balance. ‎ The stock traded up over 10% in the pre-market in reaction to the news. The $4.50 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $4.75 and then the pre-market high at $4.94. Beyond that, $6, $8 and $10 come into play. Below $4.50, targets to the downside are $4.30 and then a gap fill at $4.11. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America